All of the necessary elements of a litigation blockbuster seemed to be in place.
The science was good. The defendants — a handful of enormous pharmaceutical companies — still deny it, but two long-term studies have shown that a tiny percentage of the people who took over-the-counter drugs containing a chemical called phenylpropanolamine (PPA) were victims of PPA-associated hemorrhagic stroke. According to the epidemiological studies, thousands of people who used nonprescription diet pills or cold remedies suffered sudden bleeding into their brains as a result.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
